Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60


Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model.

Kwon KW, Lee A, Larsen SE, Baldwin SL, Coler RN, Reed SG, Cho SN, Ha SJ, Shin SJ.

Sci Rep. 2019 Oct 29;9(1):15560. doi: 10.1038/s41598-019-52146-0.


Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29.

Carrigy NB, Larsen SE, Reese V, Pecor T, Harrison M, Kuehl PJ, Hatfull GF, Sauvageau D, Baldwin SL, Finlay WH, Coler RN, Vehring R.

Antimicrob Agents Chemother. 2019 Sep 16. pii: AAC.00871-19. doi: 10.1128/AAC.00871-19. [Epub ahead of print]


The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases.

Baldwin SL, Larsen SE, Ordway D, Cassell G, Coler RN.

PLoS Negl Trop Dis. 2019 Feb 14;13(2):e0007083. doi: 10.1371/journal.pntd.0007083. eCollection 2019 Feb. Review.


Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment.

Larsen SE, Baldwin SL, Orr MT, Reese VA, Pecor T, Granger B, Dubois Cauwelaert N, Podell BK, Coler RN.

Vaccines (Basel). 2018 May 24;6(2). pii: E30. doi: 10.3390/vaccines6020030.


Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection.

Baldwin SL, Hsu FC, Van Hoeven N, Gage E, Granger B, Guderian JA, Larsen SE, Lorenzo EC, Haynes L, Reed SG, Coler RN.

Front Immunol. 2018 Feb 19;9:295. doi: 10.3389/fimmu.2018.00295. eCollection 2018.


Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines.

Allen JD, Owino SO, Carter DM, Crevar CJ, Reese VA, Fox CB, Coler RN, Reed SG, Baldwin SL, Ross TM.

Vaccine. 2017 Sep 12;35(38):5209-5216. doi: 10.1016/j.vaccine.2017.07.107. Epub 2017 Aug 5.


A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.

Van Hoeven N, Fox CB, Granger B, Evers T, Joshi SW, Nana GI, Evans SC, Lin S, Liang H, Liang L, Nakajima R, Felgner PL, Bowen RA, Marlenee N, Hartwig A, Baldwin SL, Coler RN, Tomai M, Elvecrog J, Reed SG, Carter D.

Sci Rep. 2017 Apr 21;7:46426. doi: 10.1038/srep46426.


Antigen presentation by B cells guides programing of memory CD4+ T-cell responses to a TLR4-agonist containing vaccine in mice.

Dubois Cauwelaert N, Baldwin SL, Orr MT, Desbien AL, Gage E, Hofmeyer KA, Coler RN.

Eur J Immunol. 2016 Dec;46(12):2719-2729. doi: 10.1002/eji.201646399. Epub 2016 Nov 9.


Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen.

Baldwin SL, Roeffen W, Singh SK, Tiendrebeogo RW, Christiansen M, Beebe E, Carter D, Fox CB, Howard RF, Reed SG, Sauerwein R, Theisen M.

Vaccine. 2016 Apr 27;34(19):2207-15. doi: 10.1016/j.vaccine.2016.03.016. Epub 2016 Mar 17.


Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.

Baldwin SL, Reese VA, Huang PW, Beebe EA, Podell BK, Reed SG, Coler RN.

Clin Vaccine Immunol. 2015 Dec 9;23(2):137-47. doi: 10.1128/CVI.00458-15. Print 2016 Feb.


Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.

Stavaru C, Onu A, Lupulescu E, Tucureanu C, Rasid O, Vlase E, Coman C, Caras I, Ghiorghisor A, Berbecila L, Tofan V, Bowen RA, Marlenee N, Hartwig A, Bielefeldt-Ohmann H, Baldwin SL, Van Hoeven N, Vedvick TS, Huynh C, O'Hara MK, Noah DL, Fox CB.

Hum Vaccin Immunother. 2016 Apr 2;12(4):1009-26. doi: 10.1080/21645515.2015.1111495. Epub 2015 Nov 30.


Atmospheric Ar and Ne returned from mantle depths to the Earth's surface by forearc recycling.

Baldwin SL, Das JP.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14174-9. doi: 10.1073/pnas.1424122112. Epub 2015 Nov 5.


Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.

Elewski BE, Aly R, Baldwin SL, González Soto RF, Rich P, Weisfeld M, Wiltz H, Zane LT, Pollak R.

J Am Acad Dermatol. 2015 Jul;73(1):62-9. doi: 10.1016/j.jaad.2015.04.010. Epub 2015 May 5.


The ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative.

Baldwin SL, Reese V, Granger B, Orr MT, Ireton GC, Coler RN, Reed SG.

Clin Vaccine Immunol. 2014 Sep;21(9):1309-13. doi: 10.1128/CVI.00372-14. Epub 2014 Jul 16.


Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis.

Shanley CA, Ireton GC, Baldwin SL, Coler RN, Reed SG, Basaraba RJ, Orme IM.

Tuberculosis (Edinb). 2014 Mar;94(2):140-7. doi: 10.1016/ Epub 2013 Sep 7.


Immunisation with ID83 fusion protein induces antigen-specific cell mediated and humoral immune responses in cattle.

Jones GJ, Steinbach S, Clifford D, Baldwin SL, Ireton GC, Coler RN, Reed SG, Vordermeier HM.

Vaccine. 2013 Oct 25;31(45):5250-5. doi: 10.1016/j.vaccine.2013.08.051. Epub 2013 Sep 5.


Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.

Orr MT, Fox CB, Baldwin SL, Sivananthan SJ, Lucas E, Lin S, Phan T, Moon JJ, Vedvick TS, Reed SG, Coler RN.

J Control Release. 2013 Nov 28;172(1):190-200. doi: 10.1016/j.jconrel.2013.07.030. Epub 2013 Aug 9.


Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells.

Baldwin SL, Ching LK, Pine SO, Moutaftsi M, Lucas E, Vallur A, Orr MT, Bertholet S, Reed SG, Coler RN.

J Immunol. 2013 Sep 1;191(5):2514-2525. doi: 10.4049/jimmunol.1301161. Epub 2013 Jul 31.


Clinical vaccine development for H5N1 influenza.

Clegg CH, Rininger JA, Baldwin SL.

Expert Rev Vaccines. 2013 Jul;12(7):767-77. doi: 10.1586/14760584.2013.811178. Review.


Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults.

McElhaney JE, Coler RN, Baldwin SL.

Expert Rev Vaccines. 2013 Jul;12(7):759-66. doi: 10.1586/14760584.2013.811193. Review.


Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses.

Desbien AL, Van Hoeven N, Reed SJ, Casey AC, Laurance JD, Baldwin SL, Duthie MS, Reed SG, Carter D.

Biotechniques. 2013 Jun;54(6):345-8. doi: 10.2144/000114041.


Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy.

Fox CB, Barnes V L, Evers T, Chesko JD, Vedvick TS, Coler RN, Reed SG, Baldwin SL.

Influenza Other Respir Viruses. 2013 Sep;7(5):815-26. doi: 10.1111/irv.12031. Epub 2012 Nov 5.


Adjuvant solution for pandemic influenza vaccine production.

Clegg CH, Roque R, Van Hoeven N, Perrone L, Baldwin SL, Rininger JA, Bowen RA, Reed SG.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17585-90. doi: 10.1073/pnas.1207308109. Epub 2012 Oct 8.


Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.

Fox CB, Baldwin SL, Vedvick TS, Angov E, Reed SG.

Clin Vaccine Immunol. 2012 Oct;19(10):1633-40. Epub 2012 Aug 15.


Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment.

Coler RN, Bertholet S, Pine SO, Orr MT, Reese V, Windish HP, Davis C, Kahn M, Baldwin SL, Reed SG.

J Infect Dis. 2013 Apr 15;207(8):1242-52. doi: 10.1093/infdis/jis425. Epub 2012 Aug 13.


Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions.

Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS.

AAPS PharmSciTech. 2012 Jun;13(2):498-506. doi: 10.1208/s12249-012-9771-x. Epub 2012 Mar 14.


The importance of adjuvant formulation in the development of a tuberculosis vaccine.

Baldwin SL, Bertholet S, Reese VA, Ching LK, Reed SG, Coler RN.

J Immunol. 2012 Mar 1;188(5):2189-97. doi: 10.4049/jimmunol.1102696. Epub 2012 Jan 30.


Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

Fox CB, Baldwin SL, Duthie MS, Reed SG, Vedvick TS.

Vaccine. 2011 Nov 28;29(51):9563-72. doi: 10.1016/j.vaccine.2011.08.089. Epub 2011 Sep 9.


Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay.

Ching LK, Mompoint F, Guderian JA, Picone A, Orme IM, Coler RN, Reed SG, Baldwin SL.

J Immunol Methods. 2011 Oct 28;373(1-2):54-62. doi: 10.1016/j.jim.2011.07.021. Epub 2011 Aug 3.


Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.

Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, Laughlin EM, Duthie MS, Fox CB, Carter D, Friede M, Vedvick TS, Reed SG.

PLoS One. 2011 Jan 26;6(1):e16333. doi: 10.1371/journal.pone.0016333.


Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions.

Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, Friede M.

Vaccine. 2011 Jan 17;29(4):644-9. doi: 10.1016/j.vaccine.2010.11.043. Epub 2010 Dec 4.


A synthetic adjuvant to enhance and expand immune responses to influenza vaccines.

Coler RN, Baldwin SL, Shaverdian N, Bertholet S, Reed SJ, Raman VS, Lu X, DeVos J, Hancock K, Katz JM, Vedvick TS, Duthie MS, Clegg CH, Van Hoeven N, Reed SG.

PLoS One. 2010 Oct 27;5(10):e13677. doi: 10.1371/journal.pone.0013677.


A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.

Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, Phan T, Orme IM, Vedvick TS, Baldwin SL, Coler RN, Reed SG.

Sci Transl Med. 2010 Oct 13;2(53):53ra74. doi: 10.1126/scitranslmed.3001094.


Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth.

Soman NR, Baldwin SL, Hu G, Marsh JN, Lanza GM, Heuser JE, Arbeit JM, Wickline SA, Schlesinger PH.

J Clin Invest. 2009 Sep;119(9):2830-42. doi: 10.1172/JCI38842. Epub 2009 Aug 10.


Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.

Baldwin SL, Shaverdian N, Goto Y, Duthie MS, Raman VS, Evers T, Mompoint F, Vedvick TS, Bertholet S, Coler RN, Reed SG.

Vaccine. 2009 Oct 9;27(43):5956-63. doi: 10.1016/j.vaccine.2009.07.081. Epub 2009 Aug 11.


Intradermal immunization improves protective efficacy of a novel TB vaccine candidate.

Baldwin SL, Bertholet S, Kahn M, Zharkikh I, Ireton GC, Vedvick TS, Reed SG, Coler RN.

Vaccine. 2009 May 18;27(23):3063-71. doi: 10.1016/j.vaccine.2009.03.018. Epub 2009 Mar 26.


Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis.

Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N, Laughlin EM, Baldwin SL, Vedvick TS, Coler RN, Reed SG.

J Immunol. 2008 Dec 1;181(11):7948-57.


Gallbladder disease: imaging and treatment.

Baldwin SL.

Radiol Technol. 2008 Nov-Dec;80(2):131-45. Review. No abstract available.


Sensitive ultrasonic delineation of steroid treatment in living dystrophic mice with energy-based and entropy-based radio frequency signal processing.

Wallace KD, Marsh JN, Baldwin SL, Connolly AM, Keeling R, Lanza GM, Wickline SA, Hughes MS.

IEEE Trans Ultrason Ferroelectr Freq Control. 2007 Nov;54(11):2291-9.


Ultrasonic detection of the anisotropy of protein cross linking in myocardium at diagnostic frequencies.

Baldwin SL, Yang M, Marutyan KR, Wallace KD, Holland MR, Miller JG.

IEEE Trans Ultrason Ferroelectr Freq Control. 2007 Jul;54(7):1360-9.


Diffuse benign liver disease.

Baldwin SL.

Radiol Technol. 2007 Jul-Aug;78(6):476-90; quiz 491-3. Review.


Properties of an entropy-based signal receiver with an application to ultrasonic molecular imaging.

Hughes MS, McCarthy JE, Marsh JN, Arbeit JM, Neumann RG, Fuhrhop RW, Wallace KD, Znidersic DR, Maurizi BN, Baldwin SL, Lanza GM, Wickline SA.

J Acoust Soc Am. 2007 Jun;121(6):3542-57.


Measurements of the anisotropy of ultrasonic attenuation in freshly excised myocardium.

Baldwin SL, Marutyan KR, Yang M, Wallace KD, Holland MR, Miller JG.

J Acoust Soc Am. 2006 May;119(5 Pt 1):3130-9.


The frequency dependence of ultrasonic velocity and the anisotropy of dispersion in both freshly excised and formalin-fixed myocardium.

Marutyan KR, Yang M, Baldwin SL, Wallace KD, Holland MR, Miller JG.

Ultrasound Med Biol. 2006 Apr;32(4):603-10.


Elastic stiffness coefficients (c11, C33, and C13) for freshly excised and formalin-fixed myocardium from ultrasonic velocity measurements.

Yang M, Baldwin SL, Marutyan KR, Wallace KD, Holland MR, Miller JG.

J Acoust Soc Am. 2006 Mar;119(3):1880-7.


Measurements of the anisotropy of ultrasonic velocity in freshly excised and formalin-fixed myocardial tissue.

Baldwin SL, Yang M, Marutyan KR, Wallace KD, Holland MR, Miller JG.

J Acoust Soc Am. 2005 Jul;118(1):505-13.


Influence of bright intramural echoes on estimates of ultrasonic attenuation from backscattered ultrasound in excised myocardium.

Baldwin SL, Yang M, Marutyan KR, Wallace KD, Holland MR, Miller JG.

Ultrason Imaging. 2004 Oct;26(4):233-49.


Estimating myocardial attenuation from M-mode ultrasonic backscatter.

Baldwin SL, Marutyan KR, Yang M, Wallace KD, Holland MR, Miller JG.

Ultrasound Med Biol. 2005 Apr;31(4):477-84.


Effects of region-of-interest length on estimates of myocardial ultrasonic attenuation and backscatter.

Baldwin SL, Holland MR, Sosnovik DE, Miller JG.

Med Phys. 2005 Feb;32(2):418-26.


Pliocene eclogite exhumation at plate tectonic rates in eastern Papua New Guinea.

Baldwin SL, Monteleone BD, Webb LE, Fitzgerald PG, Grove M, Hill EJ.

Nature. 2004 Sep 16;431(7006):263-7.


Supplemental Content

Loading ...
Support Center